Trevena (NASDAQ:TRVN) Now Covered by

Research analysts at started coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Trevena in a report on Tuesday, April 2nd.

Check Out Our Latest Stock Report on Trevena

Trevena Price Performance

Shares of NASDAQ:TRVN opened at $0.39 on Monday. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35. Trevena has a 1 year low of $0.30 and a 1 year high of $3.28. The business has a fifty day simple moving average of $0.50 and a 200 day simple moving average of $0.58. The firm has a market cap of $7.11 million, a price-to-earnings ratio of -0.12 and a beta of 1.10.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVNFree Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.